CHMP Backs Trixeo Aerosphere for Asthma 12+

Key Takeaways

• CHMP recommended Trixeo Aerosphere for asthma maintenance in patients ≥12 uncontrolled on medium-dose ICS/LABA.
• EMA also listed a new pMDI strength: formoterol 5 µg / glycopyrronium 18 µg / budesonide 160 µg.
• KALOS and LOGOS (~4,300 randomised) showed lung-function gains vs ICS/LABA duals; pooled analysis cut severe exacerbations.
• COPD indication remains; Commission decision still required before asthma launch.

Trixeo asthma opinion at a glance

Field	Detail
Product	Trixeo Aerosphere (BGF)
Company	AstraZeneca AB
Regulator action	CHMP positive variation opinion (23 July 2026)
New population	Asthma maintenance, ages 12+ uncontrolled on medium-dose ICS/LABA
New strength cited	FF 5 µg / GP 18 µg / BUD 160 µg pMDI
Key trials	KALOS NCT04609878; LOGOS NCT04609904
Next step	European Commission decision

What did EMA publish?

EMA said CHMP adopted a positive opinion on 23 July 2026 recommending a change to Trixeo Aerosphere's marketing authorisation. The committee adopted a new strength of the pressurised inhalation suspension associated with a new indication: maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium-dose inhaled corticosteroid and a long-acting beta2-agonist.

Primary source: EMA's Trixeo Aerosphere variation opinion.

What evidence underpins the asthma filing?

AstraZeneca said the opinion rests on the replicate Phase III KALOS and LOGOS trials comparing single-inhaler BGF with ICS/LABA duals (Symbicort pMDI and PT009). Across roughly 4,300 randomised patients, Trixeo improved lung-function endpoints versus dual therapy. In the pooled analysis prioritised for EMA, Trixeo reduced the annualised rate of severe asthma exacerbations versus combined ICS/LABA comparators, including in patients without an exacerbation in the prior year. A key secondary endpoint showed significant FEV1 improvement within five minutes after the first dose.

Registries: KALOS NCT04609878 and LOGOS NCT04609904. Journal package: Lancet Respiratory Medicine KALOS/LOGOS abstract.

How does this relate to the COPD label?

Trixeo is already authorised in the EU for maintenance treatment of moderate-to-severe COPD in adults inadequately treated by ICS/LABA or LABA/LAMA. The asthma opinion would add a second indication without replacing rescue therapy. AstraZeneca noted Trixeo/Breztri is already approved for asthma in the US, with filings elsewhere.

Context from the July plenary: EMA CHMP highlights 20–23 July 2026.

What should clinicians and payers watch?

• Exact SmPC age banding, ICS dose definitions and device training language
• Whether exacerbation benefit holds in local HTA populations with low prior-exacerbation rates
• Formulary positioning versus open triple regimens and biologics for severe asthma
• Propellant and carbon-footprint messaging already attached to next-generation Trixeo COPD supply

Trixeo remains a maintenance product, not a substitute for a short-acting rescue inhaler.

What remains uncertain?

Commission timing, national reimbursement, paediatric adolescent uptake, and real-world pneumonia or cardiovascular signals in older comorbid asthma/COPD overlap patients are still open. Cross-trial comparisons with other ICS/LABA/LAMA triples should wait for head-to-head or high-quality observational data.

Related NovaPharma coverage

• CHMP July 2026: 12 New Medicines Recommended
• CHMP Backs Obicetrapib Ubeslo and Evlarco
• EMA Backs Icotyde, First Oral IL-23R Psoriasis Drug

Frequently Asked Questions

Primary Sources

1. EMA: Trixeo Aerosphere variation opinion — 23 July 2026
2. ClinicalTrials.gov: KALOS NCT04609878
3. ClinicalTrials.gov: LOGOS NCT04609904
4. Lancet Respiratory Medicine: KALOS/LOGOS abstract